Endometrial Receptivity (ERA) at ICRM
An Endometrial Receptivity Assay (ERA) is a molecular test that determines the optimal timing for progesterone treatment to enhance the success of embryo implantation. It’s especially helpful for patients with low embryo numbers, those who have had previous unsuccessful transfers, or individuals who could benefit from personalized timing of their treatment.
At ICRM, we leverage the latest reproductive technology and molecular testing to optimize your IVF experience, and for some, that includes an ERA. Our experienced team will guide you through each step, from testing to personalized treatment adjustments, helping you achieve the best possible results on your path to parenthood.
How the ERA Works
- First: we prepare the uterus by administering a combination of estrogen and progesterone to mimic natural conditions for embryo transfer.
- Several days (typically five) before the biopsy: we initiate progesterone treatment.
- After five days of progesterone: we perform a quick, office-based endometrial biopsy. This involves:
- Conducting a speculum exam similar to a Pap smear.
- Gently inserting a thin catheter through the cervix into the uterine cavity to collect a small sample of the uterine lining.
- We then extract RNA from the sample and analyze gene expression patterns to determine which genes are active or inactive.
- Lastly: we compare the gene expression profile to a reference bank to identify whether the current timing of progesterone exposure aligns with the optimal window for embryo implantation.
Why Consider an ERA?
This testing approach helps confirm the precise window of implantation for your uterus, allowing your care team at ICRM to tailor embryo transfer timing for the best possible chance of success. Personalizing the timing of embryo transfer based on your unique receptivity profile can significantly improve outcomes in IVF treatments, especially for patients with repeated implantation failures or unique circumstances.
